Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
- Swisher, EM; Kwan, TT; Oza, AM; Tinker, AV; Ray-Coquard, I; Oaknin, A; Coleman, RL; Aghajanian, C; Konecny, GE; O'Malley, DM; Leary, A; Provencher, D; Welch, S; Chen, LM; Wahner Hendrickson, AE; Ma, L; Ghatage, P; Kristeleit, RS; Dorigo, O; Musafer, A; Kaufmann, SH; Elvin, JA; Lin, DI; Chambers, SK; Dominy, E; Vo, LT; Goble, S; Maloney, L; Giordano, H; Harding, T; Dobrovic, A; Scott, CL; Lin, KK; McNeish, IA;
Publication Year 2021-05-03, Volume 12, Issue #1, Page 2487
- Journal Title
- Nature Communications
- ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post-platinum ARIEL2 samples, RAD51C and RAD51D mutations and high-level BRCA1 promoter methylation predict response to rucaparib, similar to BRCA1/BRCA2 mutations. BRCA1 methylation loss may be a major cross-resistance mechanism to platinum and PARPi. Genomic scars associated with homologous recombination deficiency are irreversible, persisting even as platinum resistance develops, and therefore are predictive of rucaparib response only in platinum-sensitive disease. The RAS, AKT, and cell cycle pathways may be additional modulators of PARPi sensitivity.
- WEHI Research Division(s)
- Cancer Biology And Stem Cells
- PubMed ID
- Publisher's Version
- Open Access at Publisher's Site
- Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2021-05-11 04:12:17Last Modified: 2021-05-17 11:29:22